Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Shares of Merus NV (NASDAQ:MRUS) were trading at $54.35, up $12.75, or 30%, on interim data as of Feb. 27 from the phase II trial of bispecific antibody petosemtamab in combination with Merck & Co.

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

With annual revenue of $63.9 billion and a robust research pipeline, Merck continues to demonstrate its commitment to innovation in healthcare. This marks the first instance of a KEYTRUDA-based ...

The study is evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for these patients. The trial is ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Merck recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence ...